Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy B London

Showing results (81-90 of 230) with videos related to

Pageof 23
Sort By:
Blood|July 9, 2009
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425Cindy L Schwartz, Louis S Constine, Doojduen Villaluna, et al.
Journal of the National Cancer Institute|December 18, 2012
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survivalEric R Gamazon, Navin Pinto, Anuar Konkashbaev, et al.
Pediatric Blood & Cancer|March 27, 2015
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settingsNehal S Parikh, Scott C Howard, Guillermo Chantada, et al.
Pediatric Blood & Cancer|September 16, 2023
Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcomaKevin Campbell, Andrew Posner, Nan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk StratificationHannah G Bender, Meredith S Irwin, Michael D Hogarty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology GroupWendy Landier, Kristin Knight, F Lennie Wong, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2019
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)Navin Pinto, Arlene Naranjo, Emily Hibbitts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group projectWendy B London, Victoria Castel, Tom Monclair, et al.
Diagnostics (Basel, Switzerland)|December 24, 2021
Validation of a Monte Carlo Modelling Based Dosimetry of Extraoral PhotobiomodulationAnna N Yaroslavsky, Amy F Juliano, Ather Adnan, et al.
Journal of Pediatric Hematology/Oncology|June 24, 2006
POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology GroupFaith H Kung, Cindy L Schwartz, Carolyn R Ferree, et al.
Pageof 23

Showing results (81-90 of 230) with videos related to

Sort By:
Pageof 23
Blood|July 9, 2009
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425Cindy L Schwartz, Louis S Constine, Doojduen Villaluna, et al.
Journal of the National Cancer Institute|December 18, 2012
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survivalEric R Gamazon, Navin Pinto, Anuar Konkashbaev, et al.
Pediatric Blood & Cancer|March 27, 2015
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settingsNehal S Parikh, Scott C Howard, Guillermo Chantada, et al.
Pediatric Blood & Cancer|September 16, 2023
Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcomaKevin Campbell, Andrew Posner, Nan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk StratificationHannah G Bender, Meredith S Irwin, Michael D Hogarty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology GroupWendy Landier, Kristin Knight, F Lennie Wong, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2019
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)Navin Pinto, Arlene Naranjo, Emily Hibbitts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group projectWendy B London, Victoria Castel, Tom Monclair, et al.
Diagnostics (Basel, Switzerland)|December 24, 2021
Validation of a Monte Carlo Modelling Based Dosimetry of Extraoral PhotobiomodulationAnna N Yaroslavsky, Amy F Juliano, Ather Adnan, et al.
Journal of Pediatric Hematology/Oncology|June 24, 2006
POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology GroupFaith H Kung, Cindy L Schwartz, Carolyn R Ferree, et al.
Pageof 23